Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) will present a corporate overview at the Leerink Partners Global Biopharma Conference. The company focuses on developing small molecules for rare genetic diseases.
03/05/2024 - 08:00 AM
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the Leerink Partners Global Biopharma Conference, being held in Miami, FL on Wednesday, March 13, 2024 at 9:20 a.m. ET. Management will also participate in one-on-one investor meetings.
The webcast of the presentation will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations . A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir (formerly known as FTX-6058), a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact: Chris Calabrese LifeSci Advisors, LLC ccalabrese@lifesciadvisors.com 917-680-5608
When will Fulcrum Therapeutics present a corporate overview at the Leerink Partners Global Biopharma Conference?
Fulcrum Therapeutics will present a corporate overview at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 9:20 a.m. ET.
Where can I access the webcast of Fulcrum Therapeutics' presentation?
The webcast of Fulcrum Therapeutics' presentation will be accessible on the company's website at https://ir.fulcrumtx.com/events-and-presentations.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be available on Fulcrum Therapeutics' website for at least 30 days following the presentation.
FULC Rankings
#4442 Ranked by Stock Gains
FULC Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About FULC
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng